Table 3 Evaluation of ESBL-E fecal carriage to tailor empirical antimicrobial therapy
Year | Authors | Design | N | Outcome | Brief results |
|---|---|---|---|---|---|
2018 | Jalalzaï et al. [30] | Monocentric, retrospective, before-and-after study | 524 SCP 545 non-SCP | Carbapenem consumption | Decrease in carbapenem exposure in patients without ESBL-E infection during the non-SCP (75 vs 61 carbapenem-days per 1000 patient-days, p = 0.01) |
2018 | Barbier et al. [39] | Inception cohort of a multicenter prospective database | 318 | ESBL-E VAP | 18 ESBL-E VAP for 361 (5%) ventilator-associated complications among ESBL-E fecal carriers |
2018 | Houard et al. [40] | Monocentric, retrospective cohort study | 410 | ESBL-E VAP | Previous ESBL-E fecal carriage as the only independent risk factor [OR 23; 95% CI (10–55), p < 0.001] Predictive value of ESBL-E fecal carriage for subsequent ESBL-E VAP: PPV 43.6%, NVP 97.3% |
2018 | Liu et al. [35] | Monocentric, retrospective nested case-control study | 9015 | ICU-acquired ESBL-E BSI | 42 ESBL-E BSI among 9015 ESBL-E fecal carriers (0.5%) Independent risk factors associated with subsequent ESBL-E BSI: Antibiotic in the past 72 h: Penicillin (OR 12.076; 95% CI 1.397–104.251, p 0.024) Cephalosporin (OR 6.900; 95% CI 1.493–31.852, p 0.013) Carbapenem (OR 5.422; 95% CI 1.228–23.907, p 0.026) Previous ICU stay (OR 1.041; 95% CI 1.009–1.075, p 0,012) Maximum body temperature (OR 8.014; 95% CI 2.408–26.620, p 0.001) |
2017 | Razazi et al. [37] | Monocentric, prospective cohort study | 6303 | ICU-acquired ESBL-E pneumonia Predictive factors for ESBL-E pneumonia among carriers | 48/843 (6%) ESBL-E fecal carriers has subsequent ICU-acquired ESBL-E pneumonia 48/111 (43%) of ICU-acquired pneumonia among ESBL-E fecal carriers were due to ESBL-E SAPSII at admission > 43 [OR 2.81 (1.16–6.79)] Colonization with Enterobacter sp. or K. pneumoniae [OR 10.96 (2.93–41.0)] Receipt of > 2 days of AMC [OR 0.24 (0.08–0.71)] |
2017 | Carbonne et al. [38] | Multicenter, retrospective cohort study | 1503 | ESBL-E pulmonary colonization | ESBL-E fecal carriage predictive values for ESBL-E pulmonary colonization: Early (≤ 5 days): NPV 99.2% (95% CI [98.7;99.6]), PPV 14.5% (95% CI [12.8;16.3]) Late (> 5 days): NPV 93.4% (95% CI [91.9;95.0]), PPV 34.4% (95% CI [31.4;37.4]) |
2016 | Barbier et al. [41] | Cause-specific hazard model based on prospective data | 16,374 | ICU-acquired ESBL-E infection Carbapenem exposure | 98/594 (16.4%) ESBL-E fecal carriers had subsequent ICU-acquired ESBL-E infection 627, 241 and 69 carbapenem-days per 1000 patient-days for respectively infected ESBL-E carriers, non-infected ESBL-E carriers and non ESBL-E carriers |
2016 | Bruyère et al. [19] | Monocentric, retrospective cohort study | 587 | ESBL-E VAP | ESBL-E fecal carriage predictive values for ESBL-E VAP: PPV 41.5%, NPV 99.4% |
2012 | Razazi et al. [34] | Monocentric, prospective, cohort study | 610 | ICU-acquired ESBL-E infection | 10% of the first episodes of ICU-acquired infections are due to ESBL-E 27% of the second episodes of ICU-acquired infections are due to ESBL-E |
2006 | Martins et al. [36] | Monocentric prospective cohort study | 231 | ICU-acquired ESBL-producing K. pneumoniae pneumonia | Previous ESBL-production K. pneumoniae is an independent risk factor ICU-acquired ESBL-producing K. pneumoniae pneumonia (OR 60.6; 95% CI 56.33–578.73) |